Head Transplantation and Spinal Cord Fusion: The Surgical Limits of Life Extension

1. Introduction: The Operation at the Edge

Head transplantation — more precisely, transplanting a donor body onto a living head — proposes moving a patient’s head, with its intact brain, onto a brain-dead donor body whose own head has been removed. If it worked, it would instantaneously reverse every bodily aging pathology: heart failure, renal failure, sarcopenia, and immune collapse would all be replaced by youthful equivalents, while the patient’s brain and memories stayed in place. Unlike brain or mind-transfer strategies, personal continuity would be preserved by construction, because the original brain is never copied or interrupted.

The proposal hinges on a single step: functionally reconnecting a completely severed human spinal cord. This article traces the idea from early animal experiments through the Canavero controversy to the present science of spinal repair, and it separates what has been demonstrated from what has been asserted. The conclusion, stated at the outset, is that no human head transplant has been credibly performed, the claimed attempts have not produced verifiable evidence, and the procedure has no defensible path to human trials until complete spinal cord transection is repaired in conventional paralysis research.

2. Historical Precedents

The modern lineage begins with the Soviet surgeon Vladimir Demikhov, who in the 1950s created two-headed dogs by grafting a donor head and forequarters onto a host animal using vascular anastomosis. The preparations survived briefly and demonstrated that a perfused, partially functioning head could be maintained on another animal’s circulation. Two decades later Robert White performed cephalic exchange transplantation in rhesus monkeys, transferring an isolated head to an isolated body by direct suture of the carotid and jugular vessels. The transplanted heads showed organised electrical activity and could track observers with their eyes and bite, but remained quadriplegic and survived only days.

These experiments are frequently misdescribed as «head transplants.» Their real content is narrower and more instructive: they proved that a head can be vascularly supported by a foreign body, and they proved that connection — not circulation — is the wall. The animals were not saved; they were conscious only in the most restricted motor sense, unable to control any part of the body below the transection.

Evidence level: demonstrated (vascular feasibility in animals, short-term).

3. The HEAVEN/Gemini Proposal

In 2013 the neurosurgeon Sergio Canavero proposed the HEAVEN protocol («head anastomosis venture»), later paired with a spinal-linkage step termed GEMINI. The design called for ultra-sharp transection of the spinal cord to minimise crushing injury (in contrast to the contusion of typical trauma), immediate apposition of the severed ends with the membrane-fusing agent polyethylene glycol (PEG), electrical stimulation to promote regrowth, and a prolonged period of induced coma and rehabilitation.

The proposal attracted intense media attention and a formal human trial was announced for 2017; a rehearsal on cadavers in China was reported, but no living-patient procedure with published outcomes followed. Later claims of a performed transplant have not been supported by peer-reviewed evidence, operative records, independent verification, or follow-up data. Mainstream neurosurgery has consistently judged the leap from small-animal spinal fusion experiments to human complete transection unjustified.

Evidence level: engineering proposal / hypothesis. No verified human case exists.

4. Spinal Cord Fusion: The Blocking Problem

4.1. Why Complete Transection Is Different

Spinal cord injury research has produced substantial gains, but almost entirely in incomplete injuries and in chronic rehabilitation, where spared tissue or residual pathways can be recruited. A complete transection is qualitatively different. Every descending and ascending axon is severed, the local vasculature and meninges are disrupted, a glial scar forms, and the proximal and distal stumps retract. Regenerating central nervous system axons face inhibitory molecules in myelin and scar tissue, and even axons that grow often fail to re-establish the precise topographic connections required for meaningful function. Restoring useful voluntary movement across a complete transection is not a matter of encouraging some regrowth; it is a matter of re-establishing millions of correctly targeted connections.

4.2. PEG and Fusogens: What Was Actually Shown

Polyethylene glycol is a hydrophilic polymer that can fuse apposed cell membranes, and Richard Borgens and colleagues reported that subcutaneous PEG administration improved recovery in rodent spinal cord injury models — one of the findings the HEAVEN proposal leans on. The important qualifications are usually dropped in popular accounts. PEG-based fusion has been studied mainly in partial or mild injuries, in small animals, and with outcomes that are contentious and not consistently replicated at the functional level. No mammalian study has demonstrated restoration of useful voluntary locomotion after a complete transection. The gap between the published experiments and the human claim is therefore very large, and the burden of proof lies with those making the claim.

4.3. The Mainstream Spinal Repair Landscape

Conventional spinal cord repair research pursues several genuinely promising directions, none of which cures complete transection: biomaterial scaffolds and guidance channels, stem cell and olfactory ensheathing cell transplantation, modulation of the glial scar and inhibitory molecules, epidural and intraspinal electrical stimulation to activate residual circuitry, and rehabilitative training that exploits neuroplasticity. Epidural stimulation in particular has produced striking functional gains in some chronically paralysed patients by re-engaging spared descending pathways, and brain-computer interfaces with spinal stimulation have enabled voluntary movement in a small number of participants. These advances are real and are the proper home of the technologies the head-transplant proposal cites. They also underline the difference between using spared pathways and reconnecting severed ones.

Evidence level: emerging (repair strategies for incomplete injury and for activating spared tissue); not established for complete transection.

5. What a «Successful» Head Transplant Would Actually Produce

It is worth being precise about outcomes, because most public discussion skips the intermediate case. A complete success — survival with full sensorimotor function — would be the most dramatic single-procedure rejuvenation imaginable, resetting every peripheral organ system at once. A partial success, which the animal precedents make far more likely, would be a conscious, sensate, quadriplegic patient dependent on lifelong immunosuppression, ventilatory support, and intensive care. That outcome prolongs suffering rather than life, and it is ethically worse than the disease it purports to treat. The history of the primate experiments is a warning about exactly this intermediate scenario, not a proof of concept for the ideal one.

Even the peripheral reset is incomplete in principle. The transplanted body carries its own history of aging and its own genome, and the patient’s head remains attached to a body whose immune system may recognise it as foreign. Long-term immunosuppression carries infection, malignancy, and organ-toxicity risks; in a head transplant, the organ at risk of rejection is the brain, making rejection potentially catastrophic rather than merely a graft failure.

6. Application to Lifespan Extension

As a longevity strategy, head transplantation would deliver the single largest instantaneous gain of any proposed intervention: an aged head on a young body, with decades of bodily aging erased in one operation. Its fatal limitation is the same as that of brain transplantation — the brain keeps aging. Neurodegeneration, accumulated vascular injury, and the aging of long-lived postmitotic cells and proteins are not cured by a new body, so the benefit is bounded by the brain’s own durability, not by the body’s. And because the spinal reconnection problem is unsolved, the realistic near-term outcome is the paralysed-patient scenario described above, which is a prolongation of disability, not of healthy life.

For these reasons the procedure should not be presented as foreseeable or as an investment in life extension. Its genuine value is as a boundary case that isolates the field’s hardest problem: the central nervous system’s failure to regenerate after complete injury. Solving that problem would transform spinal-injury medicine for millions of people long before it enabled any head transplant, and that is where the underlying science actually belongs.

7. Ethics

A head transplant would require a brain-dead donor whose body is maintained on life support, raising profound questions about the definition of death, donor consent, and the acceptable use of a body that could instead donate multiple organs to save several lives. The recipient cannot give informed consent to an unprecedented procedure with no precedent for outcome. The failure mode — a locked-in, sensate patient — imposes a harm that cannot be undone. And the resources required would divert from conventional spinal cord and transplant research with far greater expected benefit. These considerations, not only the technical barrier, are why the proposal lacks institutional support.

8. Conclusion

Head transplantation usefully concentrates the entire problem of surgical rejuvenation into a single question: can we reconnect the cord? Every genuine advance cited by its proponents — PEG sealants, electrical stimulation, sharp-transection models — belongs to spinal-injury research, where it may one day help millions of people, and where the results so far concern partial injury and marginal regeneration, not complete transection. The head transplant itself remains a provocative illustration of that goal, not a procedure: it has no verified human case, no demonstrated route through its central obstacle, and a failure mode that is ethically unacceptable. Sober assessment places it firmly in the speculative category, with its scientific value residing almost entirely in the fields it borrows from.

Sources and Key Research Centers

1. Canavero S. «HEAVEN: The head anastomosis venture Project outline for the first human head transplantation with spinal linkage (GEMINI).» Surgical Neurology International, 2013; 4(Suppl 1): S335-S342. PubMed record — The original proposal.
2. White RJ, Wolin LR, Massopust LC Jr, Taslitz N, Verdura J. «Cephalic exchange transplantation in the monkey.» Surgery, 1971; 70(1): 135-139. PubMed: 4997130 — Vascular feasibility and the connection barrier.
3. Borgens RB, Bohnert D. «Rapid recovery from spinal cord injury after subcutaneously administered polyethylene glycol.» Journal of Neuroscience Research, 2001; 66(6): 1179-1186. DOI: 10.1002/jnr.1254 — PEG-mediated repair in rodent injury models; the basis for fusion claims.
4. PubMed: PEG-assisted spinal cord repair — Animal studies and the evidence gap before human complete-transection claims.
5. PubMed: epidural stimulation and spinal cord injury — Mainstream strategies that activate spared pathways rather than reconnecting severed ones.
6. American Association of Neurological Surgeons (AANS) — Professional standards and positions relevant to experimental neuro-reconstructive surgery.